Fulltext

Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer

Soyka, Jan ; Muster, Marco ; Schmid, Daniel ; Seifert, Burkhardt ; Schick, Ulrike ; Miralbell, Raymond ; Jorcano, Sandra ; Zaugg, Kathrin ; Seifert, Hans-Helge ; Veit-Haibach, Patrick ; Strobel, Klaus ; Schaefer, Niklaus ; Husarik, Daniela ; Hany, Thomas

In: European Journal of Nuclear Medicine and Molecular Imaging, 2012, vol. 39, no. 6, p. 936-943

Add to personal list
    Title
    • Clinical impact of 18F-choline PET/CT in patients with recurrent prostate cancer
    Author
    • Soyka, Jan. Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    • Muster, Marco. Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    • Schmid, Daniel. Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    • Seifert, Burkhardt. Division of Biostatistics, Institute of Social and Preventive Medicine, University of Zurich, Zurich, Switzerland
    • Schick, Ulrike. Department of Radiation-Oncology, University Hospital Geneva, Geneva, Switzerland
    • Miralbell, Raymond. Department of Radiation-Oncology, University Hospital Geneva, Geneva, Switzerland
    • Jorcano, Sandra. Department of Radiation-Oncology, Instituto Oncológico Teknon, Barcelona, Spain
    • Zaugg, Kathrin. Department of Radiation-Oncology, University Hospital Zurich, Zurich, Switzerland
    • Seifert, Hans-Helge. Department of Urology, University Hospital Zurich, Zurich, Switzerland
    • Veit-Haibach, Patrick. Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    • Strobel, Klaus. Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    • Schaefer, Niklaus. Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    • Husarik, Daniela. Department of Radiology, University Hospital Zurich, Zurich, Switzerland
    • Hany, Thomas. Department of Nuclear Medicine, University Hospital Zurich, Raemistrasse 100, 8091, Zurich, Switzerland
    Document Type
    • Postprint
    Language
    • English
    Published in
    • European Journal of Nuclear Medicine and Molecular Imaging, 2012, vol. 39, no. 6, p. 936-943. Springer-Verlag
    Other Version
    OAI-PMH Identifier
    • oai:doc.rero.ch:312967
    Summary
    Purpose: To investigate the clinical value of 18F-fluorocholine PET/CT (CH-PET/CT) in treatment decisions in patients with recurrent prostate cancer (rPCA). Methods: The study was a retrospective evaluation of 156 patients with rPCA and CH-PET/CT for restaging. Questionnaires for each examination were sent to the referring physicians 14-64months after examination. Questions included information regarding initial extent of disease, curative first-line treatment, and the treatment plan before and after CH-PET/CT. Additionally, PSA values at diagnosis, after initial treatment, before CH-PET/CT and at the end of follow-up were also obtained from the questionnaires. Results: Mean follow-up was 42months. The mean Gleason score was 6.9 at initial diagnosis. Initial treatment was: radical prostatectomy in 110 patients, radiotherapy in 39, and combined prostatectomy and radiotherapy in 7. Median PSA values before CH-PET/CT and at the end of follow-up were 3.40ng/ml and 0.91ng/ml. PSA levels remained stable, decreased or were below measurable levels in 108 patients. PSA levels increased in 48 patients. In 75 of the 156 patients (48%) the treatment plan was changed due to the CH-PET/CT findings. In 33 patients the therapeutic plan was changed from palliative treatment to treatment with curative intent. In 15 patients treatment was changed from curative to palliative. In 8 patients treatment was changed from curative to another strategy and in 2 patients from one palliative strategy to another. In 17 patients the treatment plan was adapted. Conclusion: CH-PET/CT has an important impact on the therapeutic strategy in patients with rPCA and can help to determine an appropriate treatment